Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database

European Psychiatry

Volumn 25, Issue 4, 2010, Pages 206-213

  Serna, M C ^a,b   Cruz, I ^b   Real, J ^a,b   Gasco E ^b   Galvan L ^c  

^a UNIVERSITY OF LLEIDA   (Spain)

^b INSTITUT CATALÀ DE LA SALUT   (Spain)

^c C Agy Hlth Technol Assess Res   (Spain)

Author keywords

Antidepressant; Drug utilization review; Medication adherence; Prescribing; Primary care; Treatment

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; HETEROCYCLIC COMPOUND; MAPROTILINE; MIRTAZAPINE; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG USE; FEMALE; FOLLOW UP; GENDER BIAS; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; POLYPHARMACY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SEX RATIO; TREATMENT DURATION; AGED; DEPRESSIVE DISORDER, MAJOR; FACTUAL DATABASE; MEDICATION COMPLIANCE; MIDDLE AGED; PSYCHOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA; TIME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; DATABASES, FACTUAL; DEPRESSIVE DISORDER, MAJOR; DRUG PRESCRIPTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; POLYPHARMACY; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; TIME FACTORS;

EID: 77952427292     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2009.07.012     Document Type: Article

References (28)

1. Agency for health care policy research. Treatment of major depression. Clin Pract Guidel 1993;l2:5 [Rockville, Md, US Department of health and human services].
2. Alonso J., Angermeyer M.C., Bernert S., Bruffaerts R., Brugha T.S., Bryson H., et al. Psychotropic drug utilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004, 420:55-64.
3. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000;157:1-45.
4. Antoñanzas F. Challenges to achieving value in drug spending in a decentralized country: the Spanish case. Value Health 2003, 6:S52-S63.
5. De Las Cuevas C., Sanz E. Do therapeutic indications of antidepressants change from one year to another?. Pharmacoepidemiol Drug Saf 2004, 13:309-314.
6. Frank E. Enhancing patient outcomes: treatment adherence. J Clin Psychiatry 1997, 58(Suppl 1):11-14.
7. Gardarsdottir H., Veffen E.C.G., Stolker J.J., Egberts T.C.G., Heerdink E.R. Does the length of the first antidepressant treatment episode influence risk and time to a second episode. J Clin Psychopharmacol 2009, 29:69-72.
8. Gartlehner G., Gaynes B.N., Hansen R.A., Thieda P., DeVeaugh-Geiss A., Krebs E.E., et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 2008, 149(10):734-750.
9. Gartlehner G, Hansen RA, Thieda P, DeVeaugh-Geiss AM, Gaynes BN, Krebs EE, et al. Comparative effectiveness of second-generation antidepressants in the pharmacologic treatment of adult depression. Comparative effectiveness review No.7-EHC007-EF. Rockville, MC: Agency for Healthcare Research and Quality; 2007 .Accessed at: on 30 September 2008. http://www.effectivehealthcare.ahrq.gov/reports/final.cfm.
10. Geddes J.R., Carney S.M., Davies C., Furukawa T.A., Kupfer D.J., Frank E., et al. Relapse prevention with antidepressant drug treatment in depressive disorders. Lancet 2003, 361. 653-651.
11. Haider S.I., Johnell K., Weitoft G.R., Thorslund M., Fastbom J. The influence of educational level on polypharmacy and inappropriate drug use: a register-based study of more than 600,000 older people. J Am Geriatr Soc 2009, 57(1):62-69.
12. Keller M.B., Hirschfeld R.M.A., Kemyyenaere K., Baldwin D.S. Optimizing outcomes in depression: focus on antidepressant compliance. Int Clin Psychopharmacol 2002, 17:265-271.
13. Kirsch I., Deacon B.J., Huedo-Medina T.B., Scoboria A., Moore T.J., Johnson B.T. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008, 5:e45.
14. Ley 14/1986 de 25 de abril, Ley General de Sanidad, BOE núm.112 de 24/86.
15. Licht-Struk E., van der Windt D.A.W.M., van Marwijk H.W.J., de Haan M., Beekman A.T.F. The prognosis of depression in older patients in general practice and the community. A systematic rexiew. Fam Pract 2007, 24:168-180.
16. Meijer W.E., Heerdink E.R., Leufkens H.G., Herings R.M., Egberts A.C., Nolen W.A. Incidence and determinants of long-term use of antidepressants. Eur J Clin Pharmacol 2004, 60:57-61.
17. Melfi C.A. Using databases for studying and comparing health care costs and resource use. Pharmacoepidemiol Drug Saf 2001, 10:399-402.
18. Morishita S., Arita S. Differential effects of ilnacipran, fluvoxamine and paroxetine for depression, especially in gender. Eur Psychiatry 2003, 18:418-420.
19. National Association of State Mental Health Program Directors, Medical Directors Council and State Medicaid Directors. NASMHPD Medical Directors.Technical. Report on Psychiatric Polypharmacy. Alexandria; 2001.
20. Nomenclator digitalis. Madrid: INSALUD; 2002.
21. Olfson M., Marcus S., Tedeschi M., Wan G. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry 2006, 163:101-108.
22. Pomerantz J.M., Finkelstein S.N., Berndt E.R., Poret A.W., Walker L.E., Alber R.C. Prescriber intent, off-label usage, and early discontinuation of antidepressants: a retrospective physician survey and data analysis. J Clin Psychiatry 2004, 65:395-404.
23. Robinson R.L., Long S.R., Chang S., Able S., Baser O., Obenchain R.L., et al. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims. J Manag Care Pharm 2006, 12(1):43-54.
24. Rush A.J., Trivedi M.H., Wisniewski S.R., Stewart J.W., Nierenberg A.A., Thase M.E., et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006, 354:1231-1242.
25. Simon G., Vonkorff M., Wagner E.H., Barlow W. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry 1993, 15:399-408.
26. Thase M.E., Entsuah R., Cantillon M., Kornstein S.G. Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. J Womens Health (Larchmt) 2005, 14:609-616.
27. Turner E.H., Matthews A.M., Linardatos E., Tell R.A., Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008, 358:252-260.
28. Vanelli M., Coca-Perraillon M. Role of patient experience in antidepressant adherence. A retrospective data analysis. Clin Ther 2008, 30:1737-1745.